News and Trends 17 Mar 2015
New Oncology finances its Genetic Test for Cancer Diagnosis
New Oncology completed a financing round to prepare the market launch of NEOliquid, a non-invasive blood test that identifies therapeutically actionable genome alterations in the circulating free tumor DNA (ctDNA) of cancer patients. New Oncology’s pan-cancer diagnostic platform NEOplus reliably detects actionable genome alterations from one single patient sample with short turn-around times. In contrast to […]